EO 14336

Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve

Signed: August 13, 2025

Published: August 19, 2025

Document Number: 2025-15823

📋Summary

This executive order directs the Department of Health and Human Services (through the Assistant Secretary for Preparedness and Response, or ASPR) to refill a federal stockpile of active pharmaceutical ingredients (APIs)—the core components used to make medicines—to reduce reliance on foreign supply chains. It mainly affects federal health and budget agencies (ASPR, HHS, OMB, and White House policy offices) and, indirectly, drug and API manufacturers that may supply the stockpile, with a preference for U.S.-made APIs when possible. Within 30 days, ASPR must identify about 26 especially critical drugs and available funding options; within 120 days it must prepare the existing SAPIR storage site; and then it must buy and store a six-month supply of APIs for those critical drugs. Within 90 days, ASPR must also update the broader essential-medicines list and submit a plan to stock and maintain six-month API supplies for additional medicines, including a cost estimate to open a second SAPIR storage site within one year.

💼Business Impact

This order most directly affects API manufacturers, contract development and manufacturing organizations (CDMOs), finished-dose drug makers that rely on imported APIs, and logistics/cold-chain/warehouse providers—because ASPR will rapidly procure and store a 6‑month API supply for ~26 “critical drugs” and then expand toward the broader essential-medicines list. The near-term opportunity is new federal demand (and potentially longer-term supplier relationships) for domestically manufactured APIs, while non-domestic API suppliers may face displacement risk as ASPR applies its “preference for obtaining domestically manufactured APIs.” Businesses should be prepared for government procurement and quality expectations: responding to ASPR solicitations, demonstrating FDA-compliant manufacturing and traceability (lot control, CoAs, stability/shelf-life data), and meeting storage/packaging/serialization and chain-of-custody requirements for stockpiled materials. Immediate actions: map which of your products/inputs align to the 26 critical drugs and the 86 essential medicines, assess your ability to scale API output within 120–180 days, get “government-ready” (SAM.gov registration, pricing/contracting capability, QA documentation), and proactively engage ASPR/HHS or prime contractors as the

Advertisement

Full Text

Federal Register :: Request Access

Request Access

Due to aggressive automated scraping of FederalRegister.gov and eCFR.gov, programmatic access to these sites is limited to access to our extensive developer APIs. Please visit FederalRegister.gov API documentation or eCFR.gov API documentation to learn more about how to access the API.

Your request has been flagged as potentially automated. If you are human user receiving this message, please complete the CAPTCHA (bot test) below and click "Request Access". You may occassionally be asked to complete the CAPTCHA again, this is normal and part of our security measures.

An official website of the United States government.

If you experiencing issues with the CAPTCHA or want to request a wider IP range, you can use the "Site Help" button found in the lower, right of this page to make a request.

Advertisement
← Back to Latest Orders